Modulight Biotherapeutics Announces $12 Million Seed Funding for Novel Optogenetic Therapy to Treat Neurological Disorders

The round was led by Jibe Ventures and LocalGlobe, with participation from Nexus NeuroTech Ventures, Redseed, Secret Chord Ventures, Fresh Fund, Saras Capital, Silverarc Capital, and Sha’ar Mivnim.

The funding marks a significant milestone for Modulight Biotherapeutics as they advance their mission to develop light-based therapeutics for the treatments of severe neurological diseases

Yeda congratulates the Modulight Biotherapeutics team and wishes them great success in advancing this groundbreaking technology.